COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services

Background: People with substance use disorders may be at a greater risk of contracting COVID-19 infection and developing medical complications. Several institutional and governmental health agencies across the world developed ad hoc guidance for substance use disorder services and care of individua...

Full description

Bibliographic Details
Main Authors: Cipriani, A. (Author), Hong, J.S.W (Author), Lingford-Hughes, A.R (Author), Macdonald, O. (Author), Ostacher, M.J (Author), Ostinelli, E.G (Author), Smith, K. (Author), Zangani, C. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04291nam a2200721Ia 4500
001 10.1186-s12888-022-03804-7
008 220511s2022 CNT 000 0 und d
020 |a 1471244X (ISSN) 
245 1 0 |a COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services 
260 0 |b BioMed Central Ltd  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s12888-022-03804-7 
520 3 |a Background: People with substance use disorders may be at a greater risk of contracting COVID-19 infection and developing medical complications. Several institutional and governmental health agencies across the world developed ad hoc guidance for substance use disorder services and care of individuals misusing substances. We aimed to synthesise the best available recommendations on management and care of people with or at risk of substance use disorders during the COVID-19 pandemic from existing guidelines published in UK, USA, Australia, Canada, New Zealand, and Singapore. Methods: We systematically searched existing guidelines and websites from 28 international institutions and governmental bodies in the context of the COVID-19 pandemic (May 4th 2021). We summarized the extracted data as answers to specific clinical questions. Results: We organised the available recommendations from 19 sources in three sections. First, we focused on general advice and recommendations for people who misuse alcohol or drugs during the COVID-19 pandemic, the design of contingency plans, safeguarding issues for children and families of service users and advice to the public, patients, and carers. Then, we summarised specific guidelines for people who use illicit drugs and related services, such as opioid substitution treatment and needle and syringe programmes. Finally, we provided a synthesis on specific recommendations for services supporting people who misuse alcohol and key topics in the field, such as management of alcohol detoxification and safe transition between supervised and unsupervised consumption. Conclusions: Available guidance reflected different approaches, ranging from being extremely cautious in providing recommendations other than generic statements to proposing adaptation of previously available guidelines to confront the challenges of the COVID-19 pandemic. After the early phase, guidance focused on reduction of infection transmission and service delivery. Guidance did not provide advice on infection prevention via vaccination programmes and service access strategies tailored to individuals with substance use disorders. © 2022, The Author(s). 
650 0 4 |a Alcohol 
650 0 4 |a alcoholism 
650 0 4 |a Alcoholism 
650 0 4 |a Article 
650 0 4 |a Australia 
650 0 4 |a Canada 
650 0 4 |a caregiver 
650 0 4 |a child 
650 0 4 |a Child 
650 0 4 |a child safety 
650 0 4 |a coronavirus disease 2019 
650 0 4 |a COVID-19 
650 0 4 |a detoxification 
650 0 4 |a disease transmission 
650 0 4 |a drug dependence 
650 0 4 |a Evidence-base recommendations 
650 0 4 |a family service 
650 0 4 |a governmental organization 
650 0 4 |a Guidelines 
650 0 4 |a health care access 
650 0 4 |a health care delivery 
650 0 4 |a health care personnel 
650 0 4 |a Health Personnel 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a infection prevention 
650 0 4 |a mental health service 
650 0 4 |a Needle and syringe programme 
650 0 4 |a New Zealand 
650 0 4 |a opiate substitution treatment 
650 0 4 |a Opioid substitution treatment 
650 0 4 |a pandemic 
650 0 4 |a Pandemics 
650 0 4 |a practice guideline 
650 0 4 |a psychology 
650 0 4 |a publication 
650 0 4 |a risk factor 
650 0 4 |a Singapore 
650 0 4 |a Substance use disorder 
650 0 4 |a Substance-Related Disorders 
650 0 4 |a United Kingdom 
650 0 4 |a United States 
700 1 |a Cipriani, A.  |e author 
700 1 |a Hong, J.S.W.  |e author 
700 1 |a Lingford-Hughes, A.R.  |e author 
700 1 |a Macdonald, O.  |e author 
700 1 |a Ostacher, M.J.  |e author 
700 1 |a Ostinelli, E.G.  |e author 
700 1 |a Smith, K.  |e author 
700 1 |a Zangani, C.  |e author 
773 |t BMC Psychiatry